GlassScriptPhysician profile
Minjoo Kim
NPI 1023478815
$1,862.28
in general payments reported to CMS, 2019-2025
19 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $29.86 · 2021: $270 · 2022: $51.19 · 2023: $247 · 2024: $644 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.35 | 2023-2025 | |
| Pfizer INC. | $286.53 | 2021-2025 | |
| Lilly USA, LLC | $183.52 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.51 | 2020-2024 | Jardiance |
| Novo Nordisk INC | $147.86 | 2019-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $116.48 | 2019 | |
| Exact Sciences Corporation | $115.88 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $75.60 | 2021 | |
| Amgen INC. | $54.44 | 2019-2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $47.47 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $47.26 | 2019 | |
| Astellas Pharma US INC | $45.45 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $44.10 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $40.14 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $18.93 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $18.77 | 2024 | Senza |
| Abbott Laboratories | $18.42 | 2021 | |
| Merck Sharp & Dohme LLC | $17.22 | 2021 | |
| Shire North American Group INC | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minjoo Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.